Atazanavir-Associated Crystalline Nephropathy.
Santoriello, Dominick; Al-Nabulsi, Majdi; Reddy, Aravinda; Salamera, Julius; D'Agati, Vivette D; Markowitz, Glen S.
Am J Kidney Dis
; 70(4): 576-580, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28579422
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis.
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.